{"id":"https://openalex.org/W2166747788","doi":"https://doi.org/10.1158/1535-7163.mct-04-0338","title":"Proteasome inhibitor therapy in multiple myeloma","display_name":"Proteasome inhibitor therapy in multiple myeloma","publication_year":2005,"publication_date":"2005-04-01","ids":{"openalex":"https://openalex.org/W2166747788","doi":"https://doi.org/10.1158/1535-7163.mct-04-0338","mag":"2166747788","pmid":"https://pubmed.ncbi.nlm.nih.gov/15827343"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.mct-04-0338","doi":"https://doi.org/10.1158/1535-7163.mct-04-0338","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-04-0338","pdf_url":"https://aacrjournals.org/mct/article-pdf/4/4/686/1870339/686-692.pdf","source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"volume":null,"type":"review","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://aacrjournals.org/mct/article-pdf/4/4/686/1870339/686-692.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5006765393","display_name":"Dharminder Chauhan","orcid":"https://orcid.org/0000-0002-5548-6138","observed_orcids":["https://orcid.org/0000-0002-5548-6138"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dharminder Chauhan","raw_affiliation_strings":["The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusettes"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusettes","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091207345","display_name":"Teru Hideshima","orcid":"https://orcid.org/0000-0003-2939-6224","observed_orcids":["https://orcid.org/0000-0003-2939-6224"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Teru Hideshima","raw_affiliation_strings":["The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusettes"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusettes","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012712111","display_name":"Constantine S. Mitsiades","orcid":"https://orcid.org/0000-0003-2321-8005","observed_orcids":["https://orcid.org/0000-0003-2321-8005"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Constantine Mitsiades","raw_affiliation_strings":["The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusettes"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusettes","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043526996","display_name":"Paul Gerard Guy Richardson","orcid":"https://orcid.org/0000-0002-7426-8865","observed_orcids":["https://orcid.org/0000-0002-7426-8865"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul Richardson","raw_affiliation_strings":["The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusettes"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusettes","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5032464400","display_name":"Kenneth Carl Anderson","orcid":"https://orcid.org/0000-0002-6418-0886","observed_orcids":["https://orcid.org/0000-0002-6418-0886"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kenneth C. Anderson","raw_affiliation_strings":["The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusettes"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusettes","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.2043,"has_fulltext":true,"cited_by_count":165,"citation_normalized_percentile":{"value":0.91397849,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":92,"max":99},"biblio":{"volume":"4","issue":"4","first_page":"686","last_page":"692"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11041","display_name":"Ubiquitin and proteasome pathways","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9739999771118164},{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":0.8830000162124634},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":1.0},{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.968999981880188},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.9430000185966492},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.8709999918937683},{"id":"https://openalex.org/keywords/bone-marrow-microenvironment","display_name":"bone marrow microenvironment","score":0.871999979019165},{"id":"https://openalex.org/keywords/translational-research","display_name":"translational research","score":0.7630000114440918},{"id":"https://openalex.org/keywords/drug-toxicity","display_name":"drug toxicity","score":0.3529999852180481}],"concepts":[{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.9484302997589111},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.905800461769104},{"id":"https://openalex.org/C2779609412","wikidata":"https://www.wikidata.org/wiki/Q203174","display_name":"Thalidomide","level":3,"score":0.7839808464050293},{"id":"https://openalex.org/C2778367456","wikidata":"https://www.wikidata.org/wiki/Q7251235","display_name":"Proteasome inhibitor","level":3,"score":0.7585940957069397},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7172983884811401},{"id":"https://openalex.org/C2780108899","wikidata":"https://www.wikidata.org/wiki/Q15366934","display_name":"Carfilzomib","level":4,"score":0.5724863409996033},{"id":"https://openalex.org/C2778684742","wikidata":"https://www.wikidata.org/wiki/Q2298283","display_name":"Melphalan","level":3,"score":0.5685949921607971},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.5649638175964355},{"id":"https://openalex.org/C2780401358","wikidata":"https://www.wikidata.org/wiki/Q422252","display_name":"Dexamethasone","level":2,"score":0.559883713722229},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5501556396484375},{"id":"https://openalex.org/C27740335","wikidata":"https://www.wikidata.org/wiki/Q14878333","display_name":"Proteasome","level":2,"score":0.5476825833320618},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.49716880917549133},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.43012890219688416},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.41821444034576416},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3267909288406372},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.16242697834968567},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.05969688296318054},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000069286","descriptor_name":"Bortezomib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001897","descriptor_name":"Boronic Acids","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008954","descriptor_name":"Models, Biological","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D011480","descriptor_name":"Protease Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D016328","descriptor_name":"NF-kappa B","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D046988","descriptor_name":"Proteasome Endopeptidase Complex","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D061988","descriptor_name":"Proteasome Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1158/1535-7163.mct-04-0338","doi":"https://doi.org/10.1158/1535-7163.mct-04-0338","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-04-0338","pdf_url":"https://aacrjournals.org/mct/article-pdf/4/4/686/1870339/686-692.pdf","source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},{"id":"pmid:15827343","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15827343","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Journal Article"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.822.7390","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.822.7390","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://mct.aacrjournals.org/content/4/4/686.full.pdf","raw_type":"text"}],"best_oa_location":{"id":"doi:10.1158/1535-7163.mct-04-0338","doi":"https://doi.org/10.1158/1535-7163.mct-04-0338","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-04-0338","pdf_url":"https://aacrjournals.org/mct/article-pdf/4/4/686/1870339/686-692.pdf","source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G1431502814","display_name":null,"funder_award_id":"CA 78373","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G1686585682","display_name":null,"funder_award_id":"50947","funder_id":"https://openalex.org/F4320332505","funder_display_name":"U.S. Public Health Service"},{"id":"https://openalex.org/G3549977710","display_name":"Host-tumor cell interaction in myeloma: therapeutic applications","funder_award_id":"5p01ca078378-15","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"},{"id":"https://openalex.org/G4933731489","display_name":"SPORE in Multiple Myeloma","funder_award_id":"P50CA100707","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G7947295115","display_name":null,"funder_award_id":"P01 CA078378-06","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G9000066536","display_name":null,"funder_award_id":"CA100707","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"}],"funders":[{"id":"https://openalex.org/F4320306439","display_name":"Multiple Myeloma Research Foundation","ror":"https://ror.org/03ww1bx13"},{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320332505","display_name":"U.S. Public Health Service","ror":"https://ror.org/05xf94514"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2166747788.pdf","grobid_xml":"https://content.openalex.org/works/W2166747788.grobid-xml"},"referenced_works_count":72,"referenced_works":["https://openalex.org/W44163030","https://openalex.org/W91158829","https://openalex.org/W143368141","https://openalex.org/W1495816485","https://openalex.org/W1520422891","https://openalex.org/W1526220366","https://openalex.org/W1549880413","https://openalex.org/W1600462418","https://openalex.org/W1630927736","https://openalex.org/W1759028523","https://openalex.org/W1772903887","https://openalex.org/W1938721925","https://openalex.org/W1941131875","https://openalex.org/W1964956799","https://openalex.org/W1966176014","https://openalex.org/W1970001436","https://openalex.org/W1977348505","https://openalex.org/W1978186903","https://openalex.org/W1980471295","https://openalex.org/W1987801916","https://openalex.org/W1994939674","https://openalex.org/W1995596496","https://openalex.org/W2002315746","https://openalex.org/W2007000374","https://openalex.org/W2007119824","https://openalex.org/W2013187395","https://openalex.org/W2032891189","https://openalex.org/W2039099638","https://openalex.org/W2039594026","https://openalex.org/W2039722337","https://openalex.org/W2039973219","https://openalex.org/W2040202840","https://openalex.org/W2043049816","https://openalex.org/W2043892945","https://openalex.org/W2052716505","https://openalex.org/W2067653691","https://openalex.org/W2081510209","https://openalex.org/W2084925682","https://openalex.org/W2085837280","https://openalex.org/W2087092058","https://openalex.org/W2087877138","https://openalex.org/W2107154392","https://openalex.org/W2108172661","https://openalex.org/W2108235071","https://openalex.org/W2116650665","https://openalex.org/W2116755440","https://openalex.org/W2119379277","https://openalex.org/W2120590293","https://openalex.org/W2121239154","https://openalex.org/W2122679146","https://openalex.org/W2134791874","https://openalex.org/W2138102966","https://openalex.org/W2146502962","https://openalex.org/W2148537814","https://openalex.org/W2152065071","https://openalex.org/W2158946057","https://openalex.org/W2161860377","https://openalex.org/W2163679078","https://openalex.org/W2168268910","https://openalex.org/W2169295136","https://openalex.org/W2169590701","https://openalex.org/W2170182861","https://openalex.org/W2170192548","https://openalex.org/W2170224969","https://openalex.org/W2288500425","https://openalex.org/W2288573335","https://openalex.org/W2292093022","https://openalex.org/W2335735158","https://openalex.org/W2362679223","https://openalex.org/W2413547554","https://openalex.org/W2589057659","https://openalex.org/W2979593893"],"related_works":["https://openalex.org/W7096176435","https://openalex.org/W2056686464","https://openalex.org/W1975966958","https://openalex.org/W2020812039","https://openalex.org/W2027348595","https://openalex.org/W2053697977","https://openalex.org/W2356409922","https://openalex.org/W2138787534","https://openalex.org/W2419203554","https://openalex.org/W2141253852"],"abstract_inverted_index":{"Multiple":[0],"myeloma":[1,32,42,116],"remains":[2],"incurable":[3],"despite":[4],"available":[5],"therapies,":[6,48],"and":[7,15,25,52,61,99,110,124],"novel":[8,111],"therapies":[9],"that":[10],"target":[11],"both":[12],"tumor":[13],"cell":[14],"bone":[16],"marrow":[17],"microenvironment":[18],"are":[19],"urgently":[20],"needed.":[21],"Preclinical":[22],"in":[23,26,40,93,128],"vitro":[24],"vivo":[27],"studies":[28,101],"show":[29],"remarkable":[30],"anti-multiple":[31],"activity":[33],"of":[34,79,90,96],"the":[35,58,66,77,94],"proteasome":[36,68],"inhibitor":[37,69],"bortezomib/PS-341":[38],"even":[39],"multiple":[41,46,81,115,129],"cells":[43],"refractory":[44],"to":[45,113],"prior":[47],"including":[49],"dexamethasone,":[50],"melphalan,":[51],"thalidomide.":[53],"Based":[54],"on":[55],"these":[56],"findings,":[57],"U.S.":[59],"Food":[60],"Drug":[62],"Administration":[63],"recently":[64],"approved":[65],"first":[67],"bortezomib":[70,107],"(Velcade),":[71],"formerly":[72],"known":[73],"as":[74],"PS-341,":[75],"for":[76,105],"treatment":[78],"relapsed/refractory":[80],"myeloma.":[82,130],"Bortezomib":[83],"therapy":[84],"has":[85],"set":[86],"an":[87],"outstanding":[88],"example":[89],"translational":[91],"research":[92],"field":[95],"oncology.":[97],"Genomics":[98],"proteomic":[100],"further":[102],"provide":[103],"rationale":[104],"combining":[106],"with":[108],"conventional":[109],"agents":[112],"inhibit":[114],"growth,":[117],"overcome":[118],"drug":[119],"resistance,":[120],"reduce":[121],"attendant":[122],"toxicity,":[123],"improve":[125],"patient":[126],"outcome":[127]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":6},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":12},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":9},{"year":2013,"cited_by_count":10},{"year":2012,"cited_by_count":10}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}